Discovery of a Highly Potent and Selective Indenoindolone Type 1 Pan-FLT3 Inhibitor
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Hatcher, John M. | - |
dc.contributor.author | Weisberg, Ellen | - |
dc.contributor.author | Sim, Taebo | - |
dc.contributor.author | Stone, Richard M. | - |
dc.contributor.author | Liu, Suiyang | - |
dc.contributor.author | Griffin, James D. | - |
dc.contributor.author | Gray, Nathanael S. | - |
dc.date.accessioned | 2021-09-03T23:58:39Z | - |
dc.date.available | 2021-09-03T23:58:39Z | - |
dc.date.created | 2021-06-18 | - |
dc.date.issued | 2016-05 | - |
dc.identifier.issn | 1948-5875 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/88697 | - |
dc.description.abstract | For a subpopulation of acute myeloid leukemia (AML) patients, the mutationally activated tyrosine kinase FLT3, has emerged as a promising target for therapy. The development of drug resistance due to mutation is a growing concern for mutant FLT3 inhibitors, such as PKC412, Quizartinib, PLX3397, and Crenolanib. Thus, there is a need to develop novel FLT3 inhibitors that overcome these mutations. Here we report the development of a novel type I ATP competitive inhibitor, JH-IX-179, that is extremely potent and selective for FLT3. JH-IX-179 also has the highest affinity for three constitutively active isoforms of FLT3 (FLT3-ITD, FLT3-N841I, and FLT3-D835V) compared to a panel 456 other kinases. The unique and specific kinase inhibition profile suggests that this chemotype may represent an attractive starting point for the development of further improved FLT3 inhibitors with therapeutic potential in tumors harboring deregulated FLT3 activity. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | AMER CHEMICAL SOC | - |
dc.subject | ACUTE MYELOID-LEUKEMIA | - |
dc.subject | INTERNAL TANDEM DUPLICATION | - |
dc.subject | TYROSINE KINASE INHIBITOR | - |
dc.subject | ACTIVATING MUTATION | - |
dc.subject | FLT3 INHIBITORS | - |
dc.subject | SORAFENIB | - |
dc.subject | THERAPY | - |
dc.subject | SU11248 | - |
dc.subject | GENE | - |
dc.subject | D835 | - |
dc.title | Discovery of a Highly Potent and Selective Indenoindolone Type 1 Pan-FLT3 Inhibitor | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Sim, Taebo | - |
dc.identifier.doi | 10.1021/acsmedchemlett.5b00498 | - |
dc.identifier.wosid | 000375969400009 | - |
dc.identifier.bibliographicCitation | ACS MEDICINAL CHEMISTRY LETTERS, v.7, no.5, pp.476 - 481 | - |
dc.relation.isPartOf | ACS MEDICINAL CHEMISTRY LETTERS | - |
dc.citation.title | ACS MEDICINAL CHEMISTRY LETTERS | - |
dc.citation.volume | 7 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 476 | - |
dc.citation.endPage | 481 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Medicinal | - |
dc.subject.keywordPlus | ACUTE MYELOID-LEUKEMIA | - |
dc.subject.keywordPlus | INTERNAL TANDEM DUPLICATION | - |
dc.subject.keywordPlus | TYROSINE KINASE INHIBITOR | - |
dc.subject.keywordPlus | ACTIVATING MUTATION | - |
dc.subject.keywordPlus | FLT3 INHIBITORS | - |
dc.subject.keywordPlus | SORAFENIB | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | SU11248 | - |
dc.subject.keywordPlus | GENE | - |
dc.subject.keywordPlus | D835 | - |
dc.subject.keywordAuthor | Acute myeloid leukemia | - |
dc.subject.keywordAuthor | FLT3 | - |
dc.subject.keywordAuthor | JH-IX-179 | - |
dc.subject.keywordAuthor | kinase inhibition profile | - |
dc.subject.keywordAuthor | chemotype | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.